Editions:  Austria · Denmark · France · Germany · Italy · Norway · Spain · Sweden · Switzerland
Advertisement

Profits shoot up for AstraZeneca

Share this article

14:31 CEST+02:00
Swedish-Anglo pharmaceuticals giant AstraZeneca reported a 23.4 percent hike in interim net profits on Thursday despite the global recession.

The firm reported profits of $3.853 billion on total revenues of $15.659 billion in the six months to the end of June 2009, up 0.2 percent on the corresponding period of 2008.

"Our business performance, in the context of tough global economic conditions, has been better than we anticipated," said Chief Executive David Brennan in the company's earnings statement.

The company explained the positive results by strong sales of the cholesterol drug Crestor and hypertension treatment Toprol XL.

"Since the first quarter several important registration applications have been submitted and approved, which displays the continued success of our research portfolio," Brenna said.

The company raised its profits forecast for the full year 2009.

Following publication of the results, Astra Zeneca's share price rose 2.21 percent at 2,865 pence on London's FTSE 100 index, which was up 1.26 percent.

Get notified about breaking news on The Local

Share this article

Advertisement

From our sponsors

'Lagom' leadership: the secret to Swedish success?

Is the Swedish approach to leadership really as special as people think? The Local asks a non-Swedish manager at telecom giant Ericsson for a frank appraisal of Swedes' so-called 'lagom' leadership style.

Advertisement
Advertisement
Jobs
Click here to start your job search
Advertisement
Advertisement

Popular articles

Advertisement
Advertisement